Physician profile
Michael Wertheim
NPI 1982643474
$106,241.61
in general payments reported to CMS, 2019-2025
67 companies · $83.33 in 2025
The $83.33 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $51K · 2020: $16K · 2021: $12K · 2022: $13K · 2023: $12K · 2024: $2,571 · 2025: $83.33.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $5,294 · Consulting Fee: $4,223 · Food and Beverage: $3,660 · Long Term Medical Supply Or Device Loan: $1,280 · Honoraria: $200 · Education: $78.59.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $5,293.50 |
| Consulting Fee | $4,222.50 |
| Food and Beverage | $3,660.48 |
| Long Term Medical Supply Or Device Loan | $1,279.73 |
| Honoraria | $200.00 |
| Education | $78.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $23,876.94 | 2019-2023 | Imfinzi, Tagrisso, Calquence |
| Genentech USA, INC. | $9,061.92 | 2019-2023 | Tecentriq |
| Takeda Pharmaceuticals U.S.A., INC. | $8,917.99 | 2019-2023 | Iclusig |
| Seagen INC. | $8,890.41 | 2019-2023 | Padcev, Adcetris, Tukysa |
| Amgen INC. | $8,869.67 | 2019-2023 | Xgeva, Vectibix, Nplate |
| E.R. Squibb & Sons, L.L.C. | $8,494.58 | 2019-2023 | Opdivo, Opdualag |
| Celgene Corporation | $5,610.82 | 2019-2023 | Reblozyl, Pomalyst |
| Mirati Therapeutics, INC. | $5,311.83 | 2023 | Krazati |
| Array Biopharma INC | $4,602.04 | 2019-2023 | Braftovi, Mektovi, Lorbrena |
| Incyte Corporation | $4,309.63 | 2019-2023 | Jakafi, Monjuvi, Pemazyre |
| Astellas Pharma US INC | $2,900.41 | 2019-2023 | Xtandi |
| Abbvie INC. | $1,781.34 | 2019-2023 | Venclexta |
| Novartis Pharmaceuticals Corporation | $1,683.68 | 2019-2025 | |
| Daiichi Sankyo INC. | $1,528.48 | 2019-2023 | Enhertu |
| Pfizer INC. | $1,494.47 | 2019-2023 |
Show all 66 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Wertheim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.